Edie A. Weller, PhD

Publications

• Leleu XP, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N, Weller E, Ghobrial IM.The Role of Serum Immunoglobulin Free Light Chain (sFLC) in response and progression in Waldenstrom Macroglobulinemia (WM).Clin Cancer Res. 2011 Mar 17.
  21415221
• Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.Weekly bort
  21345726
• Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ, , , .Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the U
  20735398
• Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in untreated
  20652865
• Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knigh
  20385792
• Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Weller EA, Melnick A, Reed JC, Horning SJ, Gascoyne RD.Expression of p21 protein predicts c
  20371683
• Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N.
  20194748
• Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relap
  20142586
• Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.Clinical and translational studies of a phase II t
  20103671
• Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I
  19786667
• Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N.High-dose zoledronic acid impacts bone remodeling with effects
  19737962
• Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.Single-agent bortezomib
  19528374
• Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ.Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: resul
  19255334
• Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM.Serum immunoglobulin free light chain correlates with tumor burde
  18452095
• Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.Clinical, radiographic, and bioche
  18413829
• Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ.Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.Leuk Lymphoma. 2007 Dec;48(12):2397-402.
  17943599
• de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, Gascoyne RD, Salles G, Weller E,.Immunohistochemical prognostic markers in diffuse large B-
  17327602
• Winter JN, Weller EA, Horning SJ, Gascoyne RD.Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement.Blood. 2007 Jan 15;109(2):844.
  17210866
• Weller EA, Miltion DK, Eisen EA, Spiegelman D.Regression calibration for logistic regression with multiple surrogates for one exposure.Journal of Statistical Planning and Inference.;137:449-461.
• Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS
  16840727
• Bellucci R, Oertelt S, Gallagher M, Li S, Zorn E, Weller E, Porcheray F, Alyea EP, Soiffer RJ, Munshi NC, Gershwin ME, Ritz J.Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic ste
  17068145
• Weller EA, Milton DK, Eisen EA, Spiegelman D.Regression calibration for logistic regression with multiple surrogates for one exposure.Journal of Statistical Planning and Inference. 2006 Sep 01;137:449-461.
• Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ.Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.Leuk Lymphoma. 2006
  16840188
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.J Clin Onco
  16754935
• Li R, Weller E, Dockery DW, Neas LM, Spiegelman D.Association of indoor nitrogen dioxide with respiratory symptoms in children: application of measurement error correction techniques to utilize data from multiple surrogates.J Expo Sci Environ Epidemiol. 2
  16519415
• Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD.Prognostic significance of Bcl-6 protein expression in DLBCL treated wi
  16449523
• Bellucci R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, Wu B, Canning C, Schlossman R, Munshi NC, Anderson KC, Ritz J.Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane re
  15692072
• Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact
  14647268
• Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP, Dranoff G, Anderson KC, Munshi NC, Ritz J.Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.Blood. 2004 Jan
  14563636
• Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL.Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.Br J H
  12786794
• Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ.Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogenei
  12463479
• Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.Immunomodulatory drug CC-5013
  12384400
• Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH, Soiffer RJ.Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.Blood. 2002 Oct 15;100(8):2697
  12351374
• Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787
  12208756
• Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC.2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Blood. 2002 Sep 15;100(6):2187-94.
  12200384
• Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM.Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.Blood.
  12200357
• Sparano JA, Weller E, Nazeer T, Habermann T, Traynor AE, Manalo J, Cassileth P.Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncolo
  12176882
• Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ.Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.Transplantation. 2002 Jul 15;74(1):49-54.
  12134098
• Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A.Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets.Am J Pathol.
  12107116
• Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, Canning C, Schlossman R, Soiffer RJ, Anderson KC, Ritz J.Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.Blood. 2002
  12036895
• Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM.Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.J Clin Oncol
  11956271
• Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patient
  11493435
• Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in pa
  11181681
• Saphner T, Weller EA, Tormey DC, Pandya KJ, Falkson CI, Stewart J, Robert NJ.21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.Am J Clin Oncol. 2000 Jun;23(3):258-62.
  10857889
• Gamel JW, Weller EA, Wesley MN, Feuer EJ.Parametric cure models of relative and cause-specific survival for grouped survival times.Comput Methods Programs Biomed. 2000 Feb;61(2):99-110.
  10661395
• Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ.Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.J Clin
  10080600
• Weller EA, Ryan LM.Testing for trend with count data.Biometrics. 1998 Jun;54(2):762-73.
  9629655